Satellos Bioscience (NASDAQ:MSLE) Announces Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Satellos Bioscience (NASDAQ:MSLE) announced its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.18), Zacks reports.

Satellos Bioscience Stock Performance

MSLE traded down $0.20 during trading on Thursday, reaching $9.82. 46,664 shares of the company were exchanged, compared to its average volume of 49,999. Satellos Bioscience has a 12-month low of $4.84 and a 12-month high of $13.39. The company has a 50-day simple moving average of $8.13. The stock has a market cap of $204.65 million, a P/E ratio of -6.14 and a beta of 1.51.

Analyst Ratings Changes

Several analysts have issued reports on the company. Wells Fargo & Company set a $18.00 target price on Satellos Bioscience in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a report on Friday, August 7th. Guggenheim assumed coverage on shares of Satellos Bioscience in a research report on Tuesday, April 28th. They set a “buy” rating and a $23.00 target price for the company. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Canaccord Genuity Group upgraded shares of Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Satellos Bioscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.75.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.